Total Payments
$347,063
2024 Payments
$29,923
Companies
23
Transactions
244
Payment Breakdown by Category
Consulting$242,606 (69.9%)
Research$40,793 (11.8%)
Travel$32,565 (9.4%)
Other$26,836 (7.7%)
Food & Beverage$4,264 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $242,606 | 72 | 69.9% |
| Unspecified | $40,793 | 39 | 11.8% |
| Travel and Lodging | $32,565 | 54 | 9.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,858 | 6 | 6.9% |
| Food and Beverage | $4,264 | 70 | 1.2% |
| Honoraria | $1,560 | 1 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,418 | 2 | 0.4% |
Payments by Type
General
$306,270
205 transactions
Research
$40,793
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $129,751 | 112 | $0 (2023) |
| Dova Pharmaceuticals | $38,382 | 16 | $0 (2021) |
| UCB SA | $33,467 | 16 | $0 (2021) |
| Amgen Inc. | $25,762 | 16 | $0 (2021) |
| SOBI, INC | $23,062 | 14 | $0 (2024) |
| Novartis Pharma AG | $14,590 | 6 | $0 (2020) |
| CSL Behring | $11,180 | 4 | $0 (2022) |
| Janssen Research & Development, LLC | $10,550 | 7 | $0 (2024) |
| Grifols USA, LLC | $9,349 | 5 | $0 (2024) |
| GENZYME CORPORATION | $8,865 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,923 | 19 | SOBI, INC ($19,183) |
| 2023 | $15,090 | 12 | NOVARTIS PHARMACEUTICALS CORPORATION ($6,764) |
| 2022 | $32,853 | 18 | Novartis Pharmaceuticals Corporation ($9,920) |
| 2021 | $53,410 | 21 | UCB SA ($14,980) |
| 2020 | $40,638 | 34 | Amgen Inc. ($14,449) |
| 2019 | $64,637 | 60 | Dova Pharmaceuticals ($28,158) |
| 2018 | $55,988 | 35 | Novartis Pharmaceuticals Corporation ($35,428) |
| 2017 | $54,526 | 45 | Novartis Pharmaceuticals Corporation ($46,226) |
All Payment Transactions
244 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $70.01 | General |
| Category: Immunology | ||||||
| 10/17/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $98.88 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/17/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $97.13 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/17/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/26/2024 | SOBI, INC | DOPTELET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,250.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/14/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $508.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/14/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $247.32 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/14/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $40.02 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/13/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $284.83 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/13/2024 | SOBI, INC | DOPTELET (Drug) | Travel and Lodging | Cash or cash equivalent | $275.84 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/15/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/25/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 05/22/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: Immunology | ||||||
| 01/30/2024 | Grifols USA, LLC | Xembify (Biological) | Consulting Fee | Cash or cash equivalent | $8,200.00 | General |
| Category: Immunology and Neurology | ||||||
| 01/30/2024 | Grifols USA, LLC | Xembify (Biological) | Travel and Lodging | Cash or cash equivalent | $241.12 | General |
| Category: Immunology and Neurology | ||||||
| 01/25/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $529.42 | General |
| Category: Immunology and Neurology | ||||||
| 01/23/2024 | SOBI, INC | DOPTELET (Drug) | Consulting Fee | Cash or cash equivalent | $8,325.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 01/19/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $50.19 | General |
| Category: Immunology and Neurology | ||||||
| 01/08/2024 | Grifols USA, LLC | Xembify (Biological) | Travel and Lodging | In-kind items and services | $327.80 | General |
| Category: Immunology and Neurology | ||||||
| 12/11/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $36.61 | General |
| 12/08/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $32.34 | General |
| Category: Neurology | ||||||
| 11/09/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $116.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/23/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: Immunology | ||||||
| 06/13/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 05/19/2023 | SOBI, INC | Gamifant (Drug) | Food and Beverage | In-kind items and services | $62.64 | General |
| Category: HEMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A review of romiplostim mechanism of action and clinical applicability | Amgen Inc. | $8,502 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $7,030 | 13 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $6,671 | 13 |
| POM in ITP | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $4,025 | 1 |
| CETB115B2302 | Novartis Pharmaceuticals Corporation | $3,614 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH PROMACTA RESEARCH | Novartis Pharmaceuticals Corporation | $1,600 | 1 |
| Surveillance Program of Romiplostim Use Connected to Pregnancy | Amgen Inc. | $1,281 | 1 |
| NGAM-10 | Octapharma USA, Inc. | $1,125 | 1 |
| JNJ-80202135-AAA | Janssen Global Services, LLC | $600.00 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $499.72 | 2 |
| "AN OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)" | UCB, Inc. | $420.00 | 1 |
| Pediatric Long Term Treatment Study | Amgen Inc. | $216.00 | 1 |
| NO8826 | Novartis Pharmaceuticals Corporation | $209.71 | 1 |
About Dr. James Bussel, MD
Dr. James Bussel, MD is a Pediatrics healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063509156.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Bussel, MD has received a total of $347,063 in payments from pharmaceutical and medical device companies, with $29,923 received in 2024. These payments were reported across 244 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($242,606).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology
- Location New York, NY
- Active Since 10/09/2006
- Last Updated 09/14/2011
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1063509156
Products in Payments
- PROMACTA (Drug) $119,691
- Doptelet (Drug) $40,918
- Nplate (Biological) $24,496
- DOPTELET (Drug) $22,863
- PROMACTA_PROMACTA_ONCOLOGY (Drug) $14,033
- Xembify (Biological) $9,349
- Alphanate (Biological) $4,985
- Tavalisse (Drug) $4,832
- EXJADE (Drug) $4,252
- Mulpleta (Drug) $1,813
- Privigen (Biological) $1,560
- PANZYGA (Biological) $1,125
- PRM_PROMACTA_ONCOLOGY (Drug) $556.79
- VYVGART (Drug) $275.55
- Gamifant (Drug) $62.64
- Gamunex-C (Biological) $43.01
- VYVGART HYTRULO (Drug) $32.34
- VONJO (Drug) $20.29
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in New York
Rosandra Reich Kaplan, M.d, M.D
Pediatrics — Payments: $300,614
Pediatrics $300,614
Dr. Michael Dolinger, Md, Mba, MD, MBA
Pediatrics — Payments: $143,865
Pediatrics $143,865
Shakeel Modak, Mbbs, MBBS
Pediatrics — Payments: $109,015
Pediatrics $109,015
Dr. George Diaz, M.d., Ph.d, M.D., PH.D
Pediatrics — Payments: $87,870
Pediatrics $87,870
Kaleb Yohay, M.d, M.D
Pediatrics — Payments: $85,737
Pediatrics $85,737
Dr. Andrew Harris, M.d, M.D
Pediatrics — Payments: $72,344
Pediatrics $72,344